Skip to main content

Table 1 Clinical features of IRIS patients

From: Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: Beneficial effect of IL-2 and GM-CSF immunotherapy

Patient CD4 T cell count before ART cells/μl CD4 T cell count at presentation of IRIS cells/μl Fold change in CD4 T cell counts from baseline to IRIS presentation CD4 T cell count after remission of IRIS cells/μl HIV-1 RNA at presentation of IRIS copies/ml Reason for admission Time on therapy* Therapy
1 7 69 9.86 202 U/D MAC 8 d4T+ddI+NFV+ImRx
2 37 70 1.89 140 U/D MAC 12 AZT+3TC+IDV+ImRx
3 4 45 11.25 93 U/D MAC 18 d4T+ddI+NFV+ImRx
4 90 280 3.11 601 U/D MAC 8 AZT+3TC+EFV+ImRx
  1. *Time in months from initiation of potent ART until diagnosis of IRIS. Drugs used in ART regime: Nucleoside analogues; Stavudine (d4T), Didanosine (ddI), Lamivudine (3TC) and Zidovudine (AZT) Protease inhibitors; Nelfinavir (NFV), Indinavir (IDV), or Non-nucleoside reverse transcriptase inhibitor; Efavirenz (EFV); ImRx = immunotherapy; MAC = Mycobacterium avium complex.